Drugs / Lynestrenol
Lynestrenol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02715232 | Feb 2017 → Dec 2020 | body integrity dysphoria | Medical University of Vienna | Unknown | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00647933 Background | Jun → Dec 2000 | infertility disorder | Organon and Co | Completed | No outcome recorded |
| Phase 4 | NCT01065220 Background | Feb 2010 → Jan 2014 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lynestrenol | “Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.” NCT00647933 ↗ |
| Known as | Linestrenol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107431 ↗ |
| Known as | Lynoestrenol | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107431 ↗ |
| Known as | NSC-37725 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107431 ↗ |
| Modality | Small molecule | — CHEMBL2107431 ↗ |
| Route | Oral | “Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.” NCT00647933 ↗ |